Bright Minds BiosciencesDRUG
About: Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.51% less ownership
Funds ownership: 4.94% [Q1] → 4.43% (-0.51%) [Q2]
14% less funds holding
Funds holding: 7 [Q1] → 6 (-1) [Q2]
19% less capital invested
Capital invested by funds: $256K [Q1] → $208K (-$47.4K) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for DRUG.
Financial journalist opinion
Based on 6 articles about DRUG published over the past 30 days